Abstract: The present invention relates to a composition including decursinol as an active ingredient for preventing or treating angina, arteriosclerosis, cerebral infarction, and hypertension. Poorly soluble decursinol was found to improve angina, arteriosclerosis, cerebral infarction, prostate hypertrophy, and diabetic hypertension by inhibiting the overgrowth of vascular endothelial cells, and is expected to be usable in the development of a composition for preventing or treating angina, arteriosclerosis, cerebral infarction, prostate hypertrophy, and diabetic hypertension.

Abstract: The present disclosure relates to an organic electroluminescent compound, a plurality of host materials, and an organic electroluminescent device comprising the same. By comprising the compound according to the present disclosure or by comprising a specific combination of compounds according to the present disclosure as a plurality of host materials, it is possible to produce an organic electroluminescent device having improved driving voltage, luminous efficiency, and/or lifetime properties compared to the conventional organic electroluminescent devices.

Abstract: The present invention relates to a composition for diagnosing or predicting a metabolic syndrome and a composition for predicting a group at high risk of expression of blood ceramide and to a single nucleotide polymorphism (SNP), derived through a genome wide association study (GWAS), capable of predicting metabolic syndrome and a group at high risk of expression of blood ceramide, which is a risk factor for metabolic syndrome. When used, a SNP marker derived by the present invention makes it possible to diagnose or predict metabolic syndrome and to predict a group at high risk of expression of blood ceramide, whereby patients suffering from the metabolic syndrome caused by a high expression of blood ceramide can be effectively diagnosed and managed. On the basis of these effects, the present invention can find wide applications in the pharmaceutical industry, etc.

Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.

Abstract: A method and a device for compensating for sensor drift are disclosed. A method for compensating for sensor drift, according to one embodiment, comprises the steps of: confirming the suitability of sensor data; defining a transformation model for transforming the sensor data; setting a loss function on the basis of the transformation model; and optimizing the transformation model on the basis of the loss function.

Abstract: The present invention relates to methods of overcoming the resistance to an EGFR (Epidermal Growth Factor Receptor)-targeting antibody through a peptide that binds specifically to neuropilin-1 (NRP1). The NRP1-specific binding-fused EGFR-targeting antibody according to the present invention is highly effective in the treatment of various tumors resistant to EGFR-targeting antibody alone.

Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.

Abstract: A display device according to an embodiment includes a display panel and a protection layer that is disposed on the display panel, wherein the protection layer includes: a first protection layer; a metal layer that overlaps the first protection layer and includes a hole; and an adhesive layer disposed between the first protection layer and the metal layer. The adhesive layer includes a first area disposed between the first protection layer and the metal layer, and a second area and a third area that are disposed in the hole, wherein a peeling strength of the second area and a peeling strength of the third area are different from each other.

Abstract: The present invention relates to methods of overcoming the resistance to an EGFR (Epidermal Growth Factor Receptor)-targeting antibody through a peptide that binds specifically to neuropilin-1 (NRP1). Moreover, the present invention relates to a fusion antibody in which a peptide that binds specifically to NRP1 is fused to an EGFR-targeting antibody, and to a composition of overcoming the resistance to an EGFR-targeting antibody alone by co-administration of the EGFR-targeting antibody and an NRP1-binding peptide-fused Fc. In addition, the fusion antibody according to the present invention, in which the NRP1-specific binding peptide is fused to an EGFR-targeting antibody, overcomes the resistance to the EGFR-targeting antibody alone in pancreatic cancer. Furthermore, the fusion antibody, in which the NRP1-specific binding peptide is fused to the EGFR-targeting antibody, also overcomes resistance to the EGFR-targeting antibody alone even in lung cancer.

Abstract: Provided is a CNT film coated substrate in which CNT is fixed to a substrate using a click reaction, so that a CNT film is uniformly formed with a high density and adhesive strength between the CNT film and the substrate is excellent to have high stability to water or an organic solvent. In the case of the conventional CNT film which was manufactured by spin coating, most of CNT was peeled off in a washing process, but in the case of the CNT film coated substrate according to the present invention, a high-density uniform CNT film coated substrate may be manufactured even after washing, and reproducibility between substrates may be secured.

Abstract: A heterodimeric Fc-fused protein and a pharmaceutical composition comprising the heterodimeric Fc-fused protein are disclosed. The heterodimeric Fc-fused protein includes first and second Fc regions of an immunoglobulin heavy chain constant region (Fc) pair and in which IL-21 is bound to at least one of the N-terminus or the C-terminus of the first Fc region and/or the second Fc region, wherein CH3 domains of the first Fc region and the second Fc region are mutated such that the formation of a heterodimer is promoted. When the heterodimeric Fc-fused protein is used, an in vivo half-life of IL-21 included in the heterodimeric Fc-fused protein may be significantly increased.

Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.

Abstract: Disclosed are a speech processing method and a speech processing apparatus in a 5G communication environment through speech processing by executing embedded artificial intelligence (AI) algorithms and/or machine learning algorithms. The speech processing method includes determining a temporary pause of reception of a first spoken utterance, outputting a first spoken response utterance as a result of speech recognition processing of a second spoken utterance received after the temporary pause, determining, as an extension of the first spoken utterance, a third spoken utterance that is received after outputting the first spoken response utterance, deleting, using a deep neural network model, a duplicate utterance part from a fourth spoken utterance that is obtained by combining the first and the third spoken utterance, and outputting a second spoken response utterance as a result of speech recognition processing of the fourth spoken utterance from which the duplicate utterance part has been deleted.

Abstract: Disclosed are a speech processing method and apparatus therefor which execute an installed artificial intelligence algorithm and/or machine learning algorithm to perform speech processing in a 5G communication environment.

Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.

Abstract: Provided is a pharmaceutical composition for preventing or treating inflammatory bowel disease (IBD) comprising a mixed extract of at least two of Aucklandia lappa Decne, Terminalia chebula Retzius, and Zingiber officinale Rosc. as an active ingredient and a method thereof, and more specifically, to a pharmaceutical composition having an inhibitory effect on monocyte adhesion in intestinal epithelial cells, an effect of inhibiting the production of inflammatory cytokines, an effect of ameliorating colitis in an animal model of dextran sodium sulfate (DSS)-induced colitis, and an effect of ameliorating Crohn's disease in an animal model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced Crohn's disease.

Abstract: Provided is a composition for preventing, improving or treating obesity, which includes a Platycodon grandiflorum extract as an active ingredient and a method for preparing the extract with an improved anti-obesity effect. The extract shows an effect of inhibiting increases in body weight and fat mass caused by a high-fat diet for normalization, an increase in fasting blood glucose and a decrease in energy expenditure in a diet-induced obesity mouse model. Further, compared to an extract prepared by a conventional extraction method, the Platycodon grandiflorum extract shows a more excellent effect of inhibiting increases in body weight and fat mass, fasting blood glucose, and blood lipid and adipokine contents in experiments, resulting in an excellent anti-obesity effect. Therefore, the Platycodon grandiflorum extract prepared is expected to be useful for preventing obesity and treating obesity-related complications that can be caused by an increase in fat mass as well as obesity.

Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.

Abstract: A display device according to an embodiment includes a display panel and a protection layer that is disposed on the display panel, wherein the protection layer includes: a first protection layer; a metal layer that overlaps the first protection layer and includes a hole; and an adhesive layer disposed between the first protection layer and the metal layer. The adhesive layer includes a first area disposed between the first protection layer and the metal layer, and a second area and a third area that are disposed in the hole, wherein a peeling strength of the second area and a peeling strength of the third area are different from each other.

Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.